• 1
    Cecka JM. The UNOS scientific renal transplant registry. In: CeckaJM, TerasakiPI, eds. Clinical Transplants. Los Angeles: UCLA Tissue Typing Laboratory, 1995: 1.
  • 2
    McKane W, Kanganas C, Preston R, et al. Treatment of calcineurin inhibitor toxicity by dose reduction plus introduction of mycophenolate mofetil. Transplant Proc 2001; 33: 1224.
  • 3
    de Mattos AM, Olyaei AJ, Bennett WM. Nephrotoxicity of immunosuppressive drugs: long-term consequences and challenges for the future. Am J Kidney Dis 2000; 35: 333.
  • 4
    Mihatsch MJ, Ryffel B, Gudat F. The differential diagnosis between rejection and cyclosporine toxicity. Kidney Int 1995; 48(Suppl. 52): 63.
  • 5
    Racusen LC, Solez K, Colvin RB, et al. The Banff 97 working classification of renal allograft pathology. Kidney Int 1999; 55: 713.
  • 6
    Häyry P. Chronic rejection: an update on the mechanism. Transplant Proc 1998; 30: 3993.
  • 7
    Tilney NL, Kusaka M, Pratschke J, Wilhelm M. Chronic rejection. Transplant Proc 1998; 30: 1590.
  • 8
    Paul LC. Immunologic risk factors for chronic renal allograft dysfunction. Transplantation 2001: 71(Suppl. 11): 17.
  • 9
    Fellström B. Nonimmune risk factors for chronic allograft dysfunction. Transplantation 2001; 71(Suppl. 11): 10.
  • 10
    Fellström B, Backman U, Larsson E, Wahlberg J. Accelerated atherosclerosis in the transplant recipient: role of hypertension. J Hum Hypertens 1998; 12: 851.
  • 11
    Cook NS, Zerwes HG, Rudin M, Beckmann N, Schuurman HJ. Chronic graft loss: dealing with the vascular alterations in solid organ transplantation. Transpl Proc 1998; 30: 2413.
  • 12
    Solez K, Axelsen RA, Benediktsson H, et al. International standardization of criteria for the histological diagnosis of renal allograft rejection – the Banff working classification of kidney transplant pathology. Kidney Int 1993; 44: 411.
  • 13
    Lindholm A, Albrechtsen D, Frodin L, Tufveson G, Persson NH, Lundgren G. Ischemic heart disease – a major cause of death and graft loss after renal transplantation in Scandinavia. Transplantation 1995; 60: 451.
  • 14
    Sehgal SN. Rapamune (sirolimus, rapamycin): an overview and mechanism of action. Ther Drug Monit 1995; 17: 660.
  • 15
    Burke SE, Lubbers NL, Chen YW, et al. Neointimal formation after balloon-induced vascular injury in Yucatan minipigs is reduced by oral rapamycin. J Cardiovasc Pharmacol 1999; 33: 829.
  • 16
    Ikonen TS, Gummert JF, Hayase M, et al. Sirolimus (rapamycin) halts and reverses progression of allograft vascular disease in non-human primates. Transplantation 2000; 70: 969.
  • 17
    Morales JM, Wrammer L, Kreis H, et al. Sirolimus does not exhibit nephrotoxicity compared to cyclosporine in renal transplant recipients. Am J Transplant 2002; 2: 436.
  • 18
    Gonwa TA, Hricik DE, Brinker K, Grinyo JM, Schena FP. Improved renal function in sirolimus-treated renal transplant patients after early cyclosporine elimination. Transplantation 2002; 74: 1560.
  • 19
    Johnson RWG, Kreis H, Oberbauer R, Brattström C, Claesson K, Eris J. Sirolimus allows early cyclosporine withdrawal in renal transplantation resulting in improved renal function and lower blood pressure. Transplantation 2001; 72: 777.
  • 20
    Oberbauer R, Kreis H, Johnson RWG, et al. Long-term improvement in renal function with sirolimus after early cyclosporine withdrawal in renal transplant recipients: 2-year results of the Rapamune maintenance regimen study. Transplantation 2003; 76: 364.
  • 21
    Dominguez J, Mahalati K, Kiberd B, McAlister VC, MacDonald AS. Conversion to rapamycin immunosuppression in renal transplant recipients: report of an initial experience. Transplantation 2000; 70: 1244.
  • 22
    Diekmann F, Waiser J, Fritsche L, Dragun D, Neumayer HH, Budde K. Conversion to rapamycin in renal allograft recipients with biopsy proven calcineurin inhibitor-induced nephrotoxicity. Transplant Proc 2001; 33: 3234.
  • 23
    Wyzgal J, Paczek L, Senatorski G, et al. Sirolimus rescue treatment in calcineurin inhibitor nephrotoxicity after kidney transplantation. Transplant Proc 2002; 34: 3185.
  • 24
    Poston RS, Billingham M, Hoyt EG, et al. Rapamycin reverses chronic graft vascular disease in a novel cardiac allograft model. Circulation 1999; 100: 67.
  • 25
    Jolicoeur EM, Qi S, Xu D, Dumont L, Daloze P, Chen H. Combination therapy of mycophenolate mofetil and rapamycin in prevention of chronic renal allograft rejection in the rat. Transplantation 2003; 75: 54.
  • 26
    Saunders RN, Bicknell GR, Nicholson ML. The impact of cyclosporine dose reduction with or without rapamycin on functional, molecular and histological markers of chronic allograft nephropathy. Transplantation 2003; 75: 772.
  • 27
    Kreis HA, Ponticelli C. Causes of late renal allograft loss: chronic allograft dysfunction, death, and other factors. Transplantation 2001: 71(Suppl. 11): 5.